Immunome (NASDAQ:IMNM – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Profitability
This table compares Immunome and Arbutus Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | N/A | -50.56% | -46.93% |
| Arbutus Biopharma | 84.22% | 90.98% | 82.34% |
Institutional & Insider Ownership
44.6% of Immunome shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 1 | 1 | 12 | 0 | 2.79 |
| Arbutus Biopharma | 0 | 1 | 1 | 0 | 2.50 |
Immunome presently has a consensus target price of $34.25, indicating a potential upside of 75.19%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 18.48%. Given Immunome’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immunome is more favorable than Arbutus Biopharma.
Valuation & Earnings
This table compares Immunome and Arbutus Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | N/A | N/A | -$212.39 million | ($2.53) | -7.73 |
| Arbutus Biopharma | $181.72 million | 4.60 | -$33.50 million | $0.79 | 5.34 |
Arbutus Biopharma has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Immunome has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
Summary
Arbutus Biopharma beats Immunome on 8 of the 13 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
